SELUTION DeNovo Trial - the largest randomized Drug Eluting Balloon trial - demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions.

The SELUTION sirolimus-eluting balloon is changing how clinicians approach coronary artery diseasetreating patients with less invasive, more natural vessel restoration strategies. Mr. Bohora played a ...

The cardiovascular device company Cordis aims to build out its drug-eluting balloon portfolio by picking up the Swiss manufacturer MedAlliance, through a transaction that could total as much as $1.1 ...

An investigational, suture-based large bore closure device intended to deliver fast and reliable vascular closure MENLO PARK, Calif., Oct. 23, 2025 /PRNewswire/ -- Cordis-X today announced that it has ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced the approval of the EXOSEAL™ ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9470f1/cordis_medical_dev) has announced the addition of the "Cordis Medical ...